Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3
1(100.0%)
1Total
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01297465Phase 3Completed

PERgoveriS In Stratified Treatment for Assisted Reproductive Technique

Role: collaborator

NCT02949908Terminated

MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)

Role: collaborator

NCT01080027Completed

Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)

Role: collaborator

All 3 trials loaded